
Treatment interruption studies during COVID-19

Community HIV Cure Workshop - CROI 2021

Simon Collins i-Base.info and RIO study





S Collins, www.i-Base.info

Community HIV Cure Workshop - March 2021

# **COVID-19 and research**

- Pandemic unexpected
- Closing international borders and travel.
- Government pay citizens.
- 115 million cases and >2.5 million deaths
- Borrowing billions/trillions of dollars.
- Availability of multiple vaccines with >90% efficacy within a year.



#### **COVID-19 and research**



- Impact on research in all countries.
  - Diverted resources (to COVID) clinics, laboratories, doctors, researchers, test kits etc
  - Cancelled operations and treatment.
  - Safety concerns increased risk from more travelling, higher risk at clinics, interventions (ATIs)

# **Cure studies and ATIs**



- Special challenges from cure research with ATIs – maybe many months.
- Issues of safety and risk were not clearly defined and only just emerging.
- Community input contributed to decisions to stop / pause / start studies.
- Decisions needed to allow for change: week 1 safe, week 2 lockdown.

# ATIs and local changes



Week 1: COVID rates low (for several wks)

Week 2: safe to interrupt ART (ATI)

Week 3: local COVID rates rebound (2nd wave):

Participants are now at increased COVID risk, ART is strongly recommended, more strict isolation, impact on QoL, anxiety and actual risk, study results lost.

# **Limited data**

 Transmission risks: participants and family: masks? distancing? Hospital setting? Best prevention?





- Impact of HIV, especially off ART.
- Other COVID risks.
- Duration of COVID-19: months vs years?

### **Two papers**



#### Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach. Michael J Peluso, Lynda Dee, Shirley Shao, Jeff Taylor, Danielle Campbell, Simon Collins, Monica Gandhi, Rowena Johnston, Steven G Deeks, John A Sauceda, Karine Dubé. Clin Inf Dis, ciaa1260, DOI: 10.1093/cid/ciaa1260 (25 August 2020), https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1260/5897039

# HIV Cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: A discussion paper. Sarah

Fidler, Sharon Lewin, Steven Deeks, Ole Sogaard, Linos Vandekerckhove, Simon Collins, Damian Kelly, Jerome Singh, Marina Caskey, John Frater. J Vir Erad. doi:10.1016/j.jve.2020.100025 (December 2020) https://www.sciencedirect.com/science/article/pii/S2055664020314746

#### Peluso et al. 1



**Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach.** *Michael Peluso et al.* 

**Principles** – importance of cure research and study question. – harm reductions approach and tracking research

**Informed consent** – to include COVID directly, including emerging risks, re-consent etc.

**Exclusion criteria** – add higher COVID risks? Age >65, serious comorbidities including diabetes, CVD, obesity? Smoking/vaping? *Race, occupation, housing not included.* 

**Study changes** – telemedicine, home bloods and fewer, masks, taxi's etc.

S Collins, www.i-Base.info

Community HIV Cure Workshop - March 2021

### Peluso et al. 2



**Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach.** *Michael Peluso et al.* 

**SARS testing** – free, baseline, before ATI, during, on request: positive result means restart ART or individualise? Opt-out permitted?

Local COVID? – to include plan for worsening COVID incidence.

**Social impact** – chance to track impact on participant needs, especially differences by population, sex, race/ethnicity, trans, older etc

**Limitations** – by city/region/hospital; changing technology (testing); by population etc

# Fidler et al. 1



HIV Cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: A discussion paper. Sarah Fidler et al.

- Ethics, risks and practical factors before re-opening HIV cure clinical trials context of RIO study.
- Importance of cure research when some regions had controlled COVID19: but ATIs > 6 months, 12 months
- Individualise decision based on both COVID and study details.
- **Minimise participant risk** of catching SARS-CoV-2 from increased visits, increased inflammation, worse COVID outcomes, worse ATI outcomes, access to ART supply.

# Fidler et al. 2



HIV Cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: A discussion paper. Sarah Fidler et al.

#### Risk assessment summary:

- Limit high risk groups in entry criteria.
- Expand access to testing before and during ATI, early restart ART if COVID symptoms and confirmed PCR.
- Limit clinic visits, home sampling.
- Flexibility to local changes.
- Updated and revised patient information and consent.
- Proactive use of vaccines when available, inclusion with study? Add to entry criteria?

# Vaccine update

- Vaccines and roll out significantly changes risk.
- Will ATI studies require vaccine cover?
- Define minimum cover: one dose?





• Changing incidence of variants.

# Conclusion



- HIV researchers responded rapidly to new changes from COVID-19
- Continued commitment to cure research.
- Prioritised participant safety.
- Restarting studies now being planned including RIO: i-base.info/rio



# Thanks



- Richard Jefferys
- Lynda Dee
- Community Cure Workshop
- Sarah Fidler, RIO study



Ref: Barney Graham – AVAC talk on COVID vaccines

S Collins, www.i-Base.info

Community HIV Cure Workshop - March 2021